Sikiric · Pharmaceuticals (Basel, Switzerland) 2025 · narrative review · n=?

Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System.

Cited 7 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Narrative review synthesizing preclinical mechanisms and animal studies without human clinical data

PubMed 40573323 · doi:10.3390/ph18060928 · record verified 2026-08-26

What was done

This narrative review summarizes preclinical and mechanistic literature on the cytoprotective actions, safety profile, and therapeutic potential of stable gastric pentadecapeptide BPC 157. The authors examine its modulation of angiogenesis and nitric oxide system pathways across tissue healing, in vitro and in vivo tumor models, and rodent models of neurodegenerative conditions.

What was found

The abstract reports no numerical data, sample sizes, or statistical effect estimates. It qualitatively describes that BPC 157 achieves high safety in animal models without reaching an LD1, modulates angiogenesis without inducing pathological corneal neovascularization, regulates nitric oxide levels while reducing free radical formation, demonstrates anti-tumor effects in vitro and in vivo, and attenuates disease-like features in mouse and rat models of Parkinson's and Alzheimer's diseases.

Why it matters

The paper outlines theoretical and preclinical arguments for BPC 157 as a pleiotropic regulator of angiogenesis and nitric oxide signaling during tissue injury.

Limits

The review relies entirely on mechanistic reasoning, cell culture experiments, and animal models, with no human clinical trial data presented. The abstract reports no quantitative measurements or confidence intervals. Animal model outcomes and broad cytoprotective claims cannot be assumed to translate to clinical efficacy or safety in humans.

Cited by